Home › FDA Approves Mercks ZINPLAVA (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence
 

Keywords :   


FDA Approves Mercks ZINPLAVA (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence

2016-10-22 03:57:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZINPLAVA (bezlotoxumab) Injection 25 mg/mL. Merck anticipates making ZINPLAVA available in first quarter 2017. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of high treatment risk

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04JLR to Use Alkegens EV Battery Solutions
29.04Albany International Ceases Manufacturing in South Korea
29.04Summertone Bronzing Gel Is New from Goop
29.04Ahlstrom Announces New Divisional Structure
29.04Vinted makes first profit on used fashion
29.04USDA issues March Cold Storage report
29.04US probes Ford hands-free driving tech after crashes
29.04ABG launches new Vectra AutoSet turret rewinder
More »